Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 14;74(3):e65–e72. doi: 10.1097/MPG.0000000000003367

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

PMC Copyright notice

Trial profile. Three infants discontinued intervention due to gastrointestinal symptoms (n = 2, CF, LF+) and extensive eczema (n = 1, LF−). They remained in the study. Six infants were lost to follow-up due to early withdrawal (n = 2, Lf−, BF), gastrointestinal side effects (n = 3, CF) and extensive data collection (n = 1, BF). Additional four infants were lost to follow up at 12 months of age (reasons not given). BF = breastfed; CF = control formula; Lf− = no added lactoferrin; Lf+ = added lactoferrin.